Complement Factor H (CFH): Complete Research Profile — Alternative Pathway Regulation, AMD/aHUS Genetics, and Complement Therapeutics Research (2026)

# Complement Factor H (CFH): Complete Research Profile — Alternative Pathway Regulation, AMD/aHUS Genetics, and Complement Therapeutics Research

Research Use Only. The content below is intended for laboratory and academic research purposes. It does not describe or endorse human or animal use, dosing, or clinical protocols.

Complement Factor H (CFH) is the principal soluble regulator of the alternative complement pathway — the "brake" that keeps a powerful innate-immune amplification loop from consuming healthy host tissue. It is one of the most heavily studied proteins in complement biology for a simple reason: a single common coding variant in CFH is associated with roughly half of all age-related macular degeneration (AMD) risk in some populations, and rare loss-of-function mutations in the same gene cause atypical hemolytic uremic syndrome (aHUS). Factor H sits at the genetic and mechanistic center of the modern complement-therapeutics research field, alongside the classical-pathway initiator C1q and the lectin-pathway initiators MBL and ficolins, and downstream of the effector fragments studied in C3a/C5a anaphylatoxin research.

This guide covers Factor H's structure, its dual regulatory mechanism, the genetics that link it to AMD and aHUS, its place in the CFHR gene family, and the research tools used to study it.

Why the Alternative Pathway Needs a Brake

Unlike the classical and lectin pathways, which require a specific recognition trigger (antibody-antigen complexes or carbohydrate patterns) before they activate, the alternative pathway is always "idling." Spontaneous, low-level hydrolysis of C3 (the "tick-over" mechanism) continuously generates a small amount of C3b, which can bind covalently to any nearby surface — pathogen or host cell alike — and nucleate a C3 convertase (C3bBb) that amplifies C3b deposition exponentially. Left unchecked, this amplification loop would deposit complement on every cell surface in the body indiscriminately.

Host cells survive this constant background activation because they are decorated with regulators, and Factor H is the dominant fluid-phase one. It works by recognizing self-associated markers — principally sialic acids and glycosaminoglycans — that are abundant on healthy host surfaces and largely absent from microbial ones. This lets Factor H discriminate "self" from "non-self" and restrain complement selectively, rather than shutting the alternative pathway down globally.

Structure: Twenty Modules in a Row

Factor H is a ~155 kDa single-chain plasma glycoprotein built from 20 tandem complement control protein modules (CCPs, also called short consensus repeats or sushi domains), each roughly 60 amino acids and independently folded, connected by short flexible linkers. Small-angle X-ray scattering and analytical ultracentrifugation studies show the full-length molecule is not a rigid rod but adopts a bent, extended, and somewhat folded-back conformation in solution, which affects how its N- and C-terminal ends are positioned relative to each other on a bound surface (Morgan et al., 2012, PMID: 22389686).

Functionally, the 20 CCPs divide into two business ends connected by a long, largely structural mid-section:

• •N-terminal CCP1–4 — carries the complement-regulatory activity. This module cluster binds C3b and executes both decay-accelerating and cofactor functions (below).
• •C-terminal CCP19–20 — carries the surface-recognition activity. This module cluster binds C3b/C3d together with host glycan markers (sialic acid, heparan sulfate), which is what lets Factor H "anchor" onto self-surfaces preferentially over pathogen surfaces.
• •Mid-region CCP6–8 and CCP19–20 — additional glycosaminoglycan-binding sites that reinforce surface discrimination.

A comprehensive surface-plasmon-resonance mapping study using recombinant three-domain fragments spanning the entire 20-CCP length confirmed that C3b/C3d binding activity is concentrated at these two ends, with most of the mid-region modules contributing to overall molecular geometry rather than direct ligand contact (Haque et al., 2020, PMID: 32849614).

Mechanism: Two Ways to Shut Down a Convertase

Factor H down-regulates the alternative pathway C3 convertase (C3bBb) through two distinct, complementary activities, both mediated by the N-terminal CCP1–4 region:

1. Decay-accelerating activity (DAA) — Factor H binds the C3bBb convertase and actively displaces the Bb catalytic fragment, disassembling the enzyme complex before it can generate more C3b.

2. Cofactor activity — Factor H binds C3b and serves as an obligate cofactor for the serine protease Factor I, which cleaves C3b into inactive iC3b. Neither Factor H nor Factor I can perform this cleavage alone; the two must act as a functional pair (mirroring how MASP proteases require the MBL/ficolin recognition scaffold in the lectin pathway).

Because these two activities target the convertase from two different angles — disassembly versus proteolytic inactivation of the substrate — a single Factor H molecule engaged on a self-surface is unusually effective at extinguishing local alternative-pathway amplification before it can escalate to the terminal pathway and membrane attack complex formation.

Genetics I: Y402H and Age-Related Macular Degeneration

The single most influential finding in complement genetics of the last two decades came from a 2005 genome-wide association study that identified a common coding polymorphism in CFH — a tyrosine-to-histidine substitution at residue 402 (Y402H), located in CCP7 — as strongly associated with AMD. Individuals homozygous for the histidine risk allele had roughly 7.4-fold increased odds of AMD compared to the tyrosine/tyrosine genotype, and the variant was estimated to account for as much as half of the population-attributable risk for the disease in the studied cohort (Klein et al., 2005, Science, PMID: 15761122).

CCP7 sits in the mid-region of Factor H, away from the primary C3b-regulatory (CCP1–4) and surface-recognition (CCP19–20) modules, but it overlaps a heparin- and C-reactive-protein-binding site. The leading mechanistic model is that the 402H variant subtly weakens Factor H's ability to bind glycosaminoglycans and CRP on the retinal pigment epithelium and Bruch's membrane, reducing local complement regulation at a tissue that is unusually vulnerable to chronic low-grade complement activation over decades of aging. This single discovery reframed AMD — previously thought of primarily as an oxidative-stress and lipid-deposition disease — as, at least in substantial part, a complement dysregulation disease, and it is widely credited as the finding that launched the modern field of complement-targeted drug discovery.

Genetics II: Atypical Hemolytic Uremic Syndrome (aHUS)

At the opposite end of the severity spectrum from a common risk allele, rare heterozygous mutations and deletions affecting CFH are a leading genetic cause of atypical hemolytic uremic syndrome — a severe thrombotic microangiopathy driven by uncontrolled alternative-pathway activation on endothelial surfaces, particularly in the kidney microvasculature.

More than 60% of aHUS-associated CFH mutations cluster in the C-terminal CCP19–20 region — precisely the surface-recognition module pair described above. Functional characterization of these mutant proteins shows that most retain normal decay-accelerating and cofactor activity in fluid phase (measured with soluble C3b), but are severely impaired at binding C3b/C3d and heparin on cell surfaces, and show correspondingly reduced binding to cultured endothelial cells. In practice this means the mutant Factor H circulates at a normal concentration and regulates fluid-phase complement normally, but simply fails to "dock" onto endothelial surfaces where regulation is needed most — a mechanistically elegant explanation for why aHUS is a surface-restricted, tissue-specific disease rather than a systemic complement deficiency (Józsi et al., 2006, J Am Soc Nephrol, PMID: 16338962).

A second, acquired route to the same phenotype involves autoantibodies against Factor H, most often directed at the same C-terminal region and frequently co-occurring with homozygous deletion of the paralogous CFHR1 and CFHR3 genes — a genetic architecture that is now a standard part of aHUS diagnostic genetic panels.

The CFHR Gene Family: Factor H's Complicating Relatives

CFH sits in a gene cluster on chromosome 1q31.3 alongside five paralogous genes — CFHR1 through CFHR5 (Complement Factor H-Related proteins). These CFHR proteins share CCP-domain homology with Factor H's C-terminal surface-binding region but lack the N-terminal regulatory CCPs, meaning they can bind the same surface ligands (C3b, glycans) without directly inhibiting the convertase. The current working model treats several CFHR proteins as competitive antagonists that displace Factor H from surfaces without providing equivalent regulation — a "de-regulation" mechanism now recognized as a distinct axis of alternative-pathway dysregulation alongside outright Factor H deficiency or dysfunction. Copy-number variation in this gene cluster (deletions, duplications, and CFH-CFHR hybrid genes formed by non-allelic homologous recombination) is a recurring theme in aHUS genetics and an active area of structural-genomics research.

Where Factor H Fits Among the Complement Regulators

Notice the pattern: Factor H is functionally the alternative-pathway counterpart to C4BP in the classical/lectin pathways, while Factor B plays the opposite role — it is the convertase-forming enzyme that Factor H is built to disassemble.

Complement Therapeutics: Why Factor H Biology Matters for Drug Research

Factor H genetics validated the alternative pathway as a druggable axis in human disease years before the first complement-targeted drugs reached approval, and the research infrastructure built around Factor H — genotyping assays, hemolytic activity assays, C3b-binding assays — is now reused directly in the development and monitoring of alternative-pathway-targeted therapeutics.

The clearest example is Factor B itself. Because Factor B is the catalytic partner Factor H is built to inhibit, small-molecule Factor B inhibitors achieve therapeutically similar downstream effects to a hypothetical "Factor H mimetic" by blocking convertase formation from the opposite side. Iptacopan, an oral small-molecule Factor B inhibitor, became the first oral monotherapy approved for paroxysmal nocturnal hemoglobinuria (PNH) — a complement-mediated hemolytic disease — based on the Phase 3 APPLY-PNH and APPOINT-PNH trials, which reported hemoglobin normalization and transfusion independence in the majority of treated patients (Peffault de Latour et al., 2024, NEJM, PMID: 38477987). Long-term 48-week follow-up data confirmed durability of this response across both anti-C5-experienced and complement-inhibitor-naive patient cohorts (Risitano et al., 2025, Lancet Haematology, PMID: 40447351).

This makes Factor B inhibitor research a useful comparative reference point when studying Factor H biology: both target the same C3bBb convertase, but Factor H research illuminates the regulatory side of alternative-pathway control (why the body's own brake fails in aHUS, or is subtly weakened in AMD), while Factor B inhibitor research illuminates the pharmacological side (how to substitute for or reinforce that brake with a small molecule). Recombinant Factor H and Factor H fragment constructs are themselves being investigated as potential complement-replacement research tools for surface-restricted regulatory failure, a direct translational extension of the structural biology summarized above.

Research Methods for Studying Factor H

• •ELISA / immunoassay quantification — sandwich ELISA kits (serum, plasma, cell-culture supernatant) are the standard method for measuring total circulating Factor H concentration, useful for distinguishing quantitative deficiency from functional/structural defects in aHUS genetic workups.
• •Genotyping panels — targeted sequencing or SNP arrays for the Y402H variant (rs1061170) and multiplex ligation-dependent probe amplification (MLPA) for CFHR1-5 copy-number variants are standard components of aHUS and AMD genetic-risk research panels.
• •Surface plasmon resonance (SPR) — used to map binding kinetics of recombinant Factor H CCP-fragment constructs against C3b, C3d, heparin, and sialic-acid-mimetic surfaces; see the site's SPR methodology guide for assay design principles that transfer directly to Factor H fragment characterization.
• •Hemolytic assays — sheep or rabbit erythrocyte lysis assays remain the functional gold standard for measuring whether a Factor H variant retains normal alternative-pathway regulatory capacity in a physiologically relevant readout.
• •Cofactor cleavage assays — SDS-PAGE/Western blot-based assays that visualize Factor I-mediated C3b cleavage in the presence of a Factor H variant, used to distinguish cofactor-activity-null mutants from surface-binding-null mutants.
• •Recombinant CCP-module constructs — bacterially or mammalian-cell-expressed three- and four-domain fragments spanning the 20-CCP chain are the standard reagent format for structure-function dissection, since full-length Factor H is difficult to crystallize intact.

Common Pitfalls in Factor H Research

• •Conflating quantitative and functional deficiency. A normal total Factor H concentration by ELISA does not rule out a surface-binding-defective variant (as in most C-terminal aHUS mutations) — functional or cell-binding assays are required to detect these.
• •CFHR cross-reactivity in immunoassays. Because CFHR1-5 share sequence homology with Factor H's C-terminal CCPs, antibody-based assays not specifically validated against CFHR paralogs can overestimate true Factor H levels.
• •Ignoring CFHR copy-number status. Standard CFH sequencing can miss CFHR1/CFHR3 deletions entirely, since they are separate genes; a complete aHUS genetic workup requires copy-number-sensitive methods (MLPA or equivalent) alongside CFH sequencing.
• •Assuming fluid-phase activity predicts surface activity. As the aHUS literature demonstrates, a Factor H mutant can show entirely normal cofactor and decay-accelerating activity against soluble C3b while being functionally null on a cell surface — always pair fluid-phase biochemical assays with a surface- or cell-based binding assay.

Frequently Asked Questions

Is Factor H itself a peptide?

No — at ~155 kDa and 1,213 amino acids, Factor H is a large multidomain plasma glycoprotein, not a peptide. It is covered here because complement regulation research frequently uses short synthetic peptide fragments derived from its CCP modules (particularly CCP19–20 recognition-domain peptides) as research tools, and because it is mechanistically central to the same alternative-pathway biology that underlies related peptide and small-molecule complement research.

How does Factor H relate to the C1q and MBL articles already on this site?

C1q initiates the classical pathway, MBL and ficolins initiate the lectin pathway, and Factor H regulates (rather than initiates) the alternative pathway. All four converge on the same downstream C3/C5 convertase machinery discussed in the C3a/C5a anaphylatoxin guide — together they map the full initiator-and-regulator architecture of the complement system.

Why is a common gene variant (Y402H) associated with such a large fraction of AMD risk?

AMD is a polygenic, age-associated disease, and Y402H is unusually common (the risk allele frequency approaches 30-40% in some European-ancestry cohorts) while conferring a moderate-to-large individual effect size — a combination that produces an outsized population-attributable-risk estimate even though many carriers never develop the disease.

---

This article is for research and educational purposes only. It does not constitute medical advice, and none of the compounds, assays, or findings described are intended for human or animal therapeutic use outside of properly authorized clinical research.